lncRNA involvement in hepatocellular carcinoma metastasis and prognosis by Abbastabar, Maryam et al.
EXCLI Journal, 2018; 17:900-913 – ISSN 1611-2156 
Received: July 17, 2018, accepted: August 20, 2018, published: September 04, 2018 
 
 
900 
Review article: 
LNCRNA INVOLVEMENT IN HEPATOCELLULAR CARCINOMA 
METASTASIS AND PROGNOSIS 
 
Maryam Abbastabar1, Mohammad Sarfi1, Abolfazl Golestani1, Ehsan Khalili1,* 
 
1 Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical 
Sciences, Tehran, I.R. Iran 
 
* Corresponding author: Ehsan Khalili, PhD, Department of Clinical Biochemistry, School 
of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Tel: +98 21 88953004, 
Fax: +98 21 64053385, E-mail: E-khalili@sina.tums.ac.ir 
 
 
http://dx.doi.org/10.17179/excli2018-1541 
 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License  
(http://creativecommons.org/licenses/by/4.0/). 
 
 
ABSTRACT 
Eukaryotic lncRNAs are RNA molecules defined to be greater than 200 bp in length that are 
not translated to a protein and operate through several mechanisms, including participating in 
chromatin remodeling and methylation, influencing the integrity and stability of proteins and 
complexes, or acting as a sponge for miRNA inhibition. A number of recent studies have con-
centrated on the relationship between long non-coding RNAs (lncRNAs) and cancer. Hepato-
cellular carcinoma (HCC) is the most prevalent histological type of liver tumors, accounting 
for about 80 % of the cases worldwide. Lack of proper molecular markers for diagnosis of HCC 
and treatment evaluation is a significant problem. Dysregulated expression of HCC-related 
lncRNAs such as MEG-3, MALAT1, HULC, HOTAIR, and H19 have been identified and 
closely related with tumorigenesis, metastasis, prognosis and diagnosis. In this review, we sum-
marized recent highlighted functions and molecular mechanisms of the most extensively stud-
ied lncRNAs in the pathophysiology of hepatocellular carcinoma and their potential for serving 
as probable therapeutic targets.  
 
Keywords: Hepatocellular carcinoma (HCC), long non-coding RNA (lncRNAs), metastasis, 
prognosis, liver  
 
 
 
INTRODUCTION 
In humans, more than 85 % of the genome 
is transcribed. RNAs that do not encode pro-
teins are called non-coding RNAs (ncRNAs). 
Non-coding RNAs are classified into two 
groups based on their size. One group is short 
RNAs with less than 200 nucleotides such as 
miRNA, siRNA, snoRNA and the other is 
long non-coding RNAs with more than 200 
nucleotides. LncRNAs, in contrast with miR-
NAs, are less understood (Berretta and 
Morillon, 2009; Haggar and Boushey, 2009; 
ENCODE Project Consortium, 2012; 
Guttman and Rinn, 2012). XIST (X-inactive 
specific transcript) and H19 were the first 
EXCLI Journal, 2018; 17:900-913 – ISSN 1611-2156 
Received: July 17, 2018, accepted: August 20, 2018, published: September 04, 2018 
 
 
901 
lncRNAs discovered in the 1990s (Brannan et 
al., 1990; Brockdorff et al., 1992). 
XIST has a role in inactivation of X-chro-
mosome in female zygotes (Marahrens et al., 
1998). Many lncRNAs are transcribed and 
spliced by RNA polymerase II and several 
lncRNAs have both poly-A tail and 5´ cap 
(Derrien et al., 2012). Similar to protein-cod-
ing genes, lncRNAs have certain epigenetic 
modifications like H3K4me3 in the promoter 
of the gene and H3K36me3 that are seen 
throughout their genome. They generally do 
not have functional open reading frames 
(ORFs). However, this discrepancy is ob-
scured by the discovery of bifunctional RNAs 
that may possess both protein-coding and 
coding-free functions. Even though 
LncRNAs can be found in many tissues, the 
brain and central nervous system have the 
highest levels of expressed lncRNAs. The in-
tracellular location of these molecules also 
varies, as they can be found in a wide range 
of intracellular components such as the nu-
cleus, the cytoplasm, or in one or more focal 
regions of the cells. Their location may indi-
cate their likely performance (Dinger et al., 
2008; Warden et al., 2008; Ponjavic et al., 
2009). 
The basis for nomenclature of lncRNAs is 
different. Some of them are named based on 
their role, such as PRAL (P53 Regulation-As-
sociation Long Non-Coding RNA), or based 
on their tissue expression such as HULC 
(Highly upregulated in liver cancer), while 
some are named based on their genomic loca-
tion such as HOTAIR (Hox antisense inter-
genic RNA) (Warden et al., 2008). LncRNAs 
have their own functional attributes due to 
their secondary structures; they usually have 
stem-loop secondary structures (Kino et al., 
2010). They interact with other biological 
molecules such as RNA, DNA, and protein, 
and other critical factors in promoting the 
physiological activity of natural cells. These 
molecules play important roles in biological 
processes through multiple mechanisms, such 
as acting as a sponge for miRNAs inhibition, 
participating in chromatin remodeling and 
also influencing the stability of proteins 
(Quinn and Chang, 2016). Many of these mol-
ecules are associated with human diseases 
such as gastric cancer (Du et al., 2015), breast 
cancer (Gupta et al., 2010), colorectal cancer 
(Kogo et al., 2011), and non-small-cell lung 
cancer (NSCLC) (Sun et al., 2014).  
Hepatocellular carcinoma (HCC) is the 
most prevalent histological type of liver 
tumors, accounting for about 80 % of the 
cases (DeSantis et al., 2014). This malignancy 
is the seventh most common carcinoma in 
men and the ninth in women (Okuda, 1992). 
HCC has a wide variety of geographical dis-
parity. It is more prevalent in China, Taiwan, 
Korea and other countries in Southeast Asia 
and Sub-Saharan Africa (Wang et al., 1991). 
The main risk factors for hepatocellular carci-
noma are age, sex, and cirrhosis, but the main 
cause is an overdose of alcohol or chronic in-
fection with hepatitis B or hepatitis C viruses 
(Trevisani et al., 1996; Velázquez et al., 
2003). Several signaling pathways have been 
shown to be critical players in HCC such as 
the Wnt/β Catenin (Herbst and Kolligs, 2007), 
p53 (Hsu et al., 1993), Ras (Liao et al., 1997) 
and JAK/STAT pathway (Wormald and 
Hilton, 2004). Although many diagnostic and 
treatment methods are available for HCC, in-
cluding surgical resection, liver transplanta-
tion, radioembolization, radiation therapy, 
and molecularly targeted therapies (Attwa 
and El-Etreby, 2015), the absence of suitable 
molecular markers for HCC diagnosis and 
therapy evaluation is a significant problem. 
Therefore, it is critical to develop novel strat-
egies for early diagnosis, prognosis, predic-
tion, and therapeutic targets of patients with 
HCC. In our study, we focused on abridging 
the conceivable functions and molecular 
mechanisms of the most extensively studied 
lncRNAs in HCC. Numerous lncRNAs have 
been reported to be involved in metastasis and 
prognosis of hepatocellular carcinoma. This 
review summarizes selected lncRNAs that are 
dysregulated in hepatocellular carcinoma 
studies, and discusses their mechanisms and 
clinical applications (Table 1). 
EXCLI Journal, 2018; 17:900-913 – ISSN 1611-2156 
Received: July 17, 2018, accepted: August 20, 2018, published: September 04, 2018 
 
 
902 
Table 1: Summary of lncRNAs involved in the hepatocellular carcinoma 
 
LncRNA Genomic 
location  
Archetype  Function Cancer 
Phenotype 
Hcc-pathway examples Reference 
MALAT-1 11q13.1 Decoy  Oncogenic  Migration;  
Proliferation;  
Invasion;  
Metastasis 
MALAT-1  LTBP3metastasis 
MALAT-1-- mir-146-5pmigration, invasion 
MALAT-1-- mir-195 EGFR metastasis 
Li and Chen, 2013; Hou et al., 
2017; Li et al., 2017a; Liu et al., 
2018 
MEG-3 14q32.2 Decoy, scaffold  Tumor  
suppressive  
Invasion;  
Metastasis 
MEG-3--MIR-664reduced tumor growth, invasion, 
and metastasis 
MEG-3--MDM2P53reduced tumor growth 
Miyoshi et al., 2000; Vogelstein et 
al., 2000; Zhou et al., 2007; Yang 
et al., 2012; He et al., 2017b 
GAS5 1q25.1  Decoy, scaffold  Tumor  
suppressive  
Metastasis GAS5--vimentin reduced metastasis Coccia et al., 1992; Tu et al., 
2014; Chang et al., 2016 
MVIH 10q22 Decoy, scaffold 
 
Oncogenic  Proliferation;  
Migration;  
Angiogenesis 
MVIH --miR-199a Proliferation, migration 
MVIH--PGK1 angiogenesis 
Lay et al., 2000; Yuan et al., 
2012b; Kinose et al., 2015 
HOTAIR 12q13.13  Scaffold  Oncogenic Migration;  
Invasion;  
Metastasis 
HOTAIR matrix metalloproteinase-9metastasis 
HOTAIR --miR-23b-3p ZEB1EMT 
Geng et al., 2011; Yan et al., 
2016; Yang et al., 2018 
H19 11p15.5  Decoy, scaffold  Oncogenic Metastasis H19 hnRNP U/PCAF/RNAPol II and miR-
200metastasis 
Cai and Cullen, 2007; Keniry et 
al., 2012; Zhang et al., 2012 
HULC 6p24.3 Decoy, scaffold  Oncogenic Metastasis HULC-- mir372 PRKACB 
HULCZEB1 EMT 
Panzitt et al., 2007; Wang et al., 
2010; Li et al., 2016a 
DRESH 17 E1.1; 17 Scaffold  Tumor  
suppressive  
Metastasis Dresh--vimentin reduced metastasis Huang et al., 2013 
MDIG 3q11.2 Guide Oncogenic Proliferation;  
Transformation 
MDIGmodification of H3K9me3 expression of 
genes important for cell expression of genes im-
portant for cell proliferation or transformation 
Ogasawara et al., 2010; Chen et 
al., 2013 
ZEB1-AS1 10p11.22 - Oncogenic Metastasis ZEB1-AS1-- E-cadherin  EMT Hashiguchi et al., 2013; Li et al., 
2016b 
UC.134 3 Signal Tumor  
suppressive  
Metastasis UC.134 repressing YAP and stimulating Hippo  
kinase signaling 
Ni et al., 2017 
PVT-1 8q24.21 Scaffold Oncogenic Proliferation PVT-1stabilizing the NOP2 proteinproliferation Chapman et al., 2012; Wang et 
al., 2014a; Yu et al., 2016 
UCA1 19p13.12 Decoy Oncogenic Metastasis;  
Invasion 
UCA1--miR-216b FGFR1/ERK signaling Li et al., 2014; Wang et al., 2015a 
ATB - Decoy Oncogenic Metastasis;  
Invasion 
ATB--miR-200 family ZEB1 and ZEB2 EMT,  
invasion 
Yuan et al., 2014 
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METASTASIS-ASSOCIATED LUNG 
ADENOCARCINOMA TRANSCRIPT 1 
(MALAT-1)  
MALAT-1, also known as nuclear enriched 
abundant transcript-2 (NEAT-2), is located at 
human chromosome 11q13.1 and mostly situ-
ated in nuclear speckles (Li and Chen, 2013). 
This lncRNA interacts with serine/arginine 
(SR) proteins and regulates them and other 
splicing factors (Tripathi et al., 2010). It is 
highly expressed in the brain (Bernard et al., 
2010) and overexpressed in many human car-
cinomas such as colorectal cancer (Yang et 
al., 2015), non-small-cell lung cancer (Ji et 
al., 2003), endometrial stromal sarcoma 
(ESS) (Yamada et al., 2006), breast cancer 
(Guffanti et al., 2009), and HCC. MALAT-1 
has been elevated in both HCC lines and clin-
ical tissue samples. Silencing of MALAT-1 
by siRNA decreases cell proliferation and in-
hibits migration and invasion; therefore, it 
could be a novel biomarker for prediction of 
HCC recurrence following liver transplanta-
tion (Lai et al., 2012). Hou et al. (2017) 
demonstrated that hepatitis B virus X protein 
(HBx) could upregulate the long non-coding 
RNA MALAT-1 in HCC, and MALAT-1 
could further influence the expression of la-
tent transforming growth factor β-binding 
protein 3 (LTBP3), resulting in further pro-
gress and metastasis of HCC. In addition, Li 
et al. (2017a) reported that MALAT-1 acts as 
a molecular sponge for mir-146-5p to down-
regulate its expression in HCC. miR-146b-5p 
could obliterate amplification, migration, and 
invasion, and also induces apoptosis in vitro 
and in vivo. Remarkably, TNF receptor-
associated factor 6 (TRAF6) has been justi-
fied as a lead target of miR-146b-5p in HCC 
and miR-146b-5p applies the cancer oblitera-
tion functions through repressing phosphory-
lation of Akt mediated by TRAF6. In addi-
tion, Liu et al. (2018) suggested that MA-
LAT-1 acts as a circular endogenous RNA for 
miR-195. Epidermal growth factor receptor 
(EGFR) is a direct target of miR-195. Spong-
ing of miR-195 by MALAT1 exerts onco-
genic effects since miR-195 is no longer able 
to suppress the downstream target EGFR. 
MATERNALLY EXPRESSED GENE-3 
(MEG-3) 
Maternally Expressed Gene 3 (MEG-3) is 
a human equivalent of mouse gene trap locus 
2 (Gtl2) that is located at human chromosome 
14q32.2 (Miyoshi et al., 2000). Evidence sug-
gests that MEG3 is expressed in normal tis-
sues, whereas its expression is downregulated 
in tongue squamous cell carcinoma (Wang et 
al., 2014b), gastric cardiac adenocarcinoma 
(Guo et al., 2017), nasopharyngeal carcinoma 
(Chak et al., 2017) and gastric cancer (Peng et 
al., 2015). This lncRNA is downregulated in 
HCC tissues, and its overexpression inhibits 
proliferation of the HCC Huh7 cell by nega-
tive modulation of miRNA-664 which re-
duces tumor growth, invasion, and metastasis 
in the orthotopic liver cancer model (Yang et 
al., 2012; He et al., 2017b). This lncRNA also 
functions as a tumor inhibitor through P53-
dependent and P53-independent pathways. 
Zhou and his colleagues (2007) discovered 
that MEG3 induces P53 accumulation via re-
pressing murine double minute 2 (MDM2) 
expression, which degrades p53. In addition it 
has been well documented that MEG3 has an-
titumor effects in the absence of p53 
(Vogelstein et al., 2000). Li et al. (2017c) 
found that miR-26a, as a tumor suppressor, 
and MEG3 decreased significantly in HCC 
compared to matched non-malignant tissues. 
MiR-26a binds to 3'-UTR of DNA methyl-
transferase3b (DNMT3B) and suppresses its 
expression, resulting in the upregulation of 
MEG3. In this way, miR-26a inhibits cell pro-
liferation, migration, and invasion in HCC. 
 
GROWTH ARREST-SPECIFIC 5 
(GAS5) 
GAS5, which accumulates in growth-
arrested cells, is located at 1q25.1. This gene 
encodes multiple snoRNAs and lncRNAs that 
act as a ribo-repressor of the glucocorticoid 
and associated receptors (Coccia et al., 1992). 
Various functions have been related to this 
transcript, including cell development pre-
vention and apoptosis (Wang et al., 2018). It 
has therefore been recognized as a potential 
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tumor suppressor, with its inhibition linked to 
cancer in numerous diverse tissues. Tu et al. 
(2014) revealed that the expression level of 
GAS5 is reduced in HCC compared to normal 
matched tissues. It also has been proven that 
GAS5 expression is associated with HCC tu-
mor size, lymph node metastasis, and clinical 
stage. Chang et al. (2016) reported that GAS5 
participates in the epithelial mesenchymal 
transition (EMT) of HCC cells. Overexpres-
sion of GAS5 downregulates the vimentin and 
upregulates the E-cadherin level in hepatocel-
lular carcinoma cells. There is a significant 
negative association between GAS5 and the 
vimentin level in vivo (Chang et al., 2016). 
Vimentin is a 57 kDa, type III intermediate 
filament whose function is to maintain cell 
and tissue integrity. Vimentin is linked with 
tumor incursion and a poor prognosis in vari-
ous types of cancers, including hepatocellular 
carcinoma (Hu et al., 2004). These data sug-
gest an essential role for GAS5 in the molec-
ular etiology of HCC and implicate the poten-
tial application of GAS5 in HCC therapy. 
 
LNCRNA WITH ASSOCIATED  
MICROVASCULAR INVASION IN 
HCC (MVIH) 
MVIH is located at human chromosome 
10q22 at RPS24 (Ribosomal Protein S24) 
gene which is overexpressed in HCC (Yuan et 
al., 2012b), and breast cancer (Lei et al., 
2016). Presently, little is known about MVIH. 
A current study showed that MVIH might 
control HCC cell vitality by sponging and re-
pressing the expression of miR-199a (Shi et 
al., 2015). Several reports have shown that 
miR-199a acts as a tumor repressor, promotes 
tumor cell apoptosis, and inhibits cell prolif-
eration and migration in several cancers (Tian 
et al., 2014; Wang et al., 2014b; Kinose et al., 
2015). Yuan et al. (2012b) found that MVIH 
could activate tumor-inducing angiogenesis 
by diminishing the secretion of phospho-
glycerate kinase 1 (PGK1), which is a glyco-
lytic enzyme that catalyzes the conversion of 
1.3-diphosphoglycerate to 3-phosphoglycer-
ate. This enzyme can be secreted by tumor 
cells and contributes to inhibition of angio-
genesis (Lay et al., 2000). The serum level of 
MVIH is inversely correlated with the level of 
PKG1. MVIH overexpression could predict 
the recurrence of early-stage HCC in patients 
(Yuan et al., 2012b).  
 
HOX ANTISENSE INTERGENIC RNA 
(HOTAIR) 
This lncRNA's gene is situated inside the 
Homeobox C (HOXC) gene assemblage on 
chromosome 12 and is co-expressed with the 
HOXC genes (Wu et al., 2017). HOTAIR re-
cruits the polycomb repressive complex-2 
(PRC2) and Lysine-Specific Histone Deme-
thylase 1 (LSD1) to the specific site and reg-
ulates the HOXD gene expression (Yan et al., 
2016). This lncRNA has an essential function 
in the epigenetic control of gene expression. 
In this regard, HOTAIR is deregulated in var-
ious cancers like pancreatic cancer (Kim et 
al., 2013), lung cancer (Loewen et al., 2014), 
esophageal cancer (Lv et al., 2013), and HCC. 
In HCC, HOTAIR is increased compared to 
non-cancerous tissues; it acts by activating the 
Wnt/β catenin signaling pathway and is asso-
ciated with metastasis, differentiation, and 
early recurrence (Gao et al., 2016). In vitro as-
says in the HCC cell line have demonstrated 
that knockdown of HOTAIR lncRNA dimin-
ishes cell proliferation and is associated with 
decreased levels of matrix metalloproteinase-
9 and vascular endothelial growth factor pro-
tein, which are crucial for cell motility and 
metastasis (Geng et al., 2011). On the other 
hand, HOTAIR promotes invasion and metas-
tasis of HCC cells by enhancing EMT. This 
lncRNA acts as a miR-23b-3p sponge to pos-
itively regulate zinc finger E-box-binding 
homeobox 1(ZEB1), a transcription factor as-
sociated with EMT (Yang et al., 2018). In ad-
dition, Wu et al. (2018) reported that HOT-
AIR bestows its impacts on cell multiplication 
via controlling the opioid growth factor 
receptor expression, which is a negative bio-
logical regulator of cell proliferation in HCC. 
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H19 
H19 was the first imprinted non-coding 
transcript identified and has a highly con-
served secondary structure (Cai and Cullen, 
2007). H19 is co-expressed with another ma-
ternally imprinted gene, insulin-like growth 
factor 2 (IGF-2) (Jones et al., 1998). The H19 
gene behaves as an oncogene and may serve 
as a potential new target for anti-tumor ther-
apy (Matouk et al., 2007). Increased expres-
sion of H19 RNA has been shown in a large 
group of tumors such as pancreatic cancer 
(Ma et al., 2014), breast cancer (Zhang et al., 
2016) and HCC. Many studies have shown 
that H19 can interact with microRNAs and 
proteins. H19 acts as a sponge for miR-675 
that is encoded in its first exon (Keniry et al., 
2012). Furthermore, H19 is associated with 
the protein complex hnRNP U/PCAF/ 
RNAPol II and activates the miR-200 family 
by increasing histone acetylation. Zhang et al. 
(2012) demonstrated that H19 can alter the 
miR-200 pathway, thus contributing to mes-
enchymal-to-epithelial transition and repres-
sion of cancer metastasis. 
 
HIGHLY UPREGULATED IN LIVER 
CANCER NON-CODING RNA (HULC) 
HULC is located at human chromosome 
6p24.3 and is the first ncRNA with highly 
specific upregulation in HCC. It can be de-
tected in the blood of HCC patients (Panzitt et 
al., 2007). This lncRNA may act as an endog-
enous sponge that downregulates a series of 
miRNAs’ activities, including miR-372 and 
miR-200a-3p. Suppression of miR-372 re-
duces the translational repression of 
PRKACB (cAMP-dependent protein kinase 
catalytic subunit beta), which then triggers 
phosphorylation of CREB. Binding of 
phospho-CREB to the HULC promoter acti-
vates HULC expression (Wang et al., 2010). 
HULC expression is not confined to HCC 
alone, but also to those colorectal carcinomas 
that metastasize to the liver (Matouk et al., 
2009). Li et al. (2016a) suggested that miR-
200a-3p is negatively regulated by HULC, 
and HULC functions as a ceRNA to mediate 
EMT via up-regulating ZEB1 in HCC cells. 
Xiong and his colleagues (2017) found that 
ectopic expression of HULC stimulates the 
autophagy of HCC cells via harmonizing si-
lent information regulator 1 (Sirt1) protein 
and dampening of HULC sensitized HCC 
cells to antitumor reagents through suppress-
ing protective autophagy. In addition, it has 
also been found that HULC and Linc00152 
can act as novel biomarkers in predicting the 
diagnosis of HCC, and a combination of 
HULC, Linc00152, and AFP has the highest 
prediction value in HCC (Li et al., 2015). 
 
DRESH 
Hepatitis B virus (HBV) has an important 
role in human hepatocellular carcinoma 
(HCC). Many non-coding RNAs including 
miRNAs such as miR-18a (Liu et al., 2016b), 
mir-148a (Yuan et al., 2012a), mir-21 (Qiu et 
al., 2013) and lncRNAs regulated by HBx in 
HCC have important biological functions in 
cell proliferation, apoptosis, invasion, and 
metastasis. HBx protein can decrease 
lncRNAs whose expression is downregulated 
by HBx (termed lncRNA-Dreh). LncRNA-
Dreh acts as a cancer inhibitor and could at-
tach to the intermediate filament protein vi-
mentin, suppresses its expression, and alters 
the cytoskeletal structure and prevents tumor 
metastasis (Huang et al., 2013). 
 
MDIG 
MDIG was initially discovered as a min-
eral dust-induced transcript from coal miners’ 
alveolar macrophages (Zhang et al., 2005). 
The expression of MDIG is controlled by the 
c-Myc oncogene and termed as myc-induced 
nuclear antigen 53 (Mina53) (Ogasawara et 
al., 2010). High levels of MDIG expression 
have been found in lung cancer (Lu et al., 
2009), renal cell carcinoma (Ishizaki et al., 
2007), lymphoma (Teye et al., 2007), neuro-
blastoma (Fukahori et al., 2007), esophageal 
squamous cell carcinoma, and HCC 
(Tsuneoka et al., 2004). Chen et al. (2013) 
demonstrated that MDIG participates in mod-
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ification of H3K9me3 to impact the hetero-
chromatin structure of the genome, and the 
expression of genes important for cell prolif-
eration or transformation. Ogasawara et al. 
(2010) proposed that Mina53 expression is 
accelerated in HCC with a lower histological 
grade, larger diameter, or cell growth compe-
tence, and Mina53 is linked to biological ma-
lignancy of HCC. 
 
ZEB1-AS1 
Zinc finger E-box-binding homeobox 1 is 
a protein encoded by the ZEB1 gene in hu-
mans. There is a non-coding antisense tran-
script emanating from the promoters of 
ZEB1, ZEB1 antisense1 (ZEB1-AS1). ZEB1-
AS1 is frequently upregulated in HCC sam-
ples, especially in metastatic tumor tissues, 
and may serve as a valuable prognostic bi-
omarker for HCC (Li et al., 2016b). Hashigu-
chi et al. (2013) revealed that positive ZEB-1 
expression and loss of E-cadherin expression 
correlate with a poor prognosis and progres-
sion of HCC through their effect on the 
progression of EMT. 
 
UC.134 LNCRNA 
UC.134 is a novel lncRNA that inhibits 
liver tumor development by suppressing the 
CUL4A-mediated ubiquitination of LATS1 
and augmenting YAP phosphorylation. Over-
expression of uc.134 suppresses HCC cell 
proliferation, invasion, and metastasis in vitro 
and in vivo. The use of this lncRNA may pro-
vide a favorable therapeutic method by re-
pressing YAP and stimulating Hippo kinase 
signaling (Ni et al., 2017). 
 
PVT-1 AND UC200MBE.2 
The lncRNA plasmacytoma variant trans-
location 1 (PVT1) is 1716 nucleotides long. It 
is located at 8q24.21 and is a recently identi-
fied long non-coding RNA. The human PVT1 
oncogene level has been discovered to be high 
in a succession of human cancers (Barsotti et 
al., 2012; Chapman et al., 2012). Yu et al. re-
ported that lncRNAs PVT1 and uc002mbe.2 
are upregulated in the sera of HCC patients 
compared to healthy controls (Yu et al., 
2016). They demonstrated that amalgamation 
of 2 lncRNAs in the serum produces a new 
supplementary approach for HCC diagnosis. 
In addition, Wang et al. (2014a) found that 
oncofetal long non-coding RNA PVT1 stim-
ulates multiplication and acquisition of stem 
cell-like properties in hepatocellular carci-
noma cells through stabilizing the NOP2 pro-
tein. The NOP2 nucleolar protein can inten-
sify nucleolar activities and stimulate cell pro-
liferation by modifying the cell cycle and the 
hPVT1/NOP2 pathway. It is also involved in 
promoting carcinogenesis and cell prolifera-
tion and acquiring stem cell-like properties in 
HCC cells. 
 
LNCRNA-UCA1 AND WRAP53 
Urothelial carcinoma associated antigen 1 
(UCA1) is a bladder cancer-specific lncRNA 
with a total length of 1439 bp that is located 
at 19p13.12 (Li et al., 2014). UCA1 is a com-
mon molecular marker for lymph node metas-
tasis and prognosis in various cancers, includ-
ing colorectal cancer, breast cancer, esopha-
geal cancer, lung cancer, and pancreatic can-
cer (Ni et al., 2015; Wang et al., 2015b; He et 
al., 2017a). The expression of serum UCA1 is 
significantly higher in patients with HCC, al-
lowing differentiation of HCC from benign 
liver disease and healthy controls. High ex-
pression of serum UCA1 is significantly asso-
ciated with a high tumor grade, large tumor 
size, positive vascular invasion, and advanced 
TNM stage (Heng et al., 2018). Kamel et al. 
(2016) provided evidence that lncRNA-
UCA1 and WD repeat containing antisense to 
TP53 (WRAP53) are highly expressed in the 
serum of HCC patients and HCV patients. 
They reported that lncRNA-WRAP53 expres-
sion is a useful prognostic marker for RFS in 
HCC. Wang et al. (2015a) demonstrated that 
UCA1 may act as an endogenous sponge by 
directly binding to miR-216b, and downregu-
lation of miR-216b expression results in re-
pression of fibroblast growth factor receptor1 
(FGFR1) expression and activation of an 
FGFR1/ERK signaling pathway in HCC. 
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Therefore, upregulated lncRNA-UCA1 levels 
in HCC tissues are associated with the TNM 
stage, metastasis, and postoperative survival. 
 
ATB 
LncRNA activated by transforming 
growth factor beta (TGF-β) (lncRNA-ATB) is 
involved in cell proliferation and metastasis in 
a variety of cancers, including renal cell car-
cinoma, colorectal cancer, non-small-cell 
lung cancer, glioma, etc. (Iguchi et al., 2015; 
Qiu et al., 2017; Ke et al., 2017; Li et al., 
2017d). In addition, this lncRNA is upregu-
lated in hepatocellular carcinoma metastases 
and is associated with a poor prognosis. 
LncRNA-ATB upregulates ZEB1 and ZEB2 
by competitively binding to the miR-200 fam-
ily, thereby inducing EMT and invasion 
(Yuan et al., 2014). Li et al. (2018) demon-
strated that Astragaloside IV (AS-IV) signifi-
cantly downregulates lncRNA-ATB expres-
sion in a dose- and time-dependent manner in 
HCC cells. AS-IV represses EMT and migra-
tion of HCC cells. Likewise, through down-
regulation of lncRNA-ATB, AS-IV inacti-
vates IL-11/STAT3 signaling, induces HCC 
cell apoptosis, and reduces HCC cell viability. 
 
OTHER LNCRNAS IN HCC 
Recent studies have established that many 
other lncRNAs are abnormally regulated in 
HCC, including lncRNA-Low Expression in 
Tumor (lncRNA-LET), located at 15q24.1. It 
is involved in cancer suppression in numerous 
tumor types, such as cervical cancer (Jiang et 
al., 2015), nasopharyngeal carcinoma (Sun et 
al., 2015), lung adenocarcinoma (Liu et al., 
2016a), and HCC. Hypoxia can suppress 
lncRNA-LET by decreasing the histone H3 
and H4 acetylation levels in its promoter re-
gion. Furthermore, downregulation of 
lncRNA-LET may affect the accumulation 
and stability of HIF-1a mRNA under hypoxic 
conditions. It is worth noting that the tran-
script levels of the endogenous hypoxia 
marker CA9 are inversely correlated with the 
levels of lncRNA-LET in primary HCC tis-
sues, and downregulated expression of 
lncRNA-LET is associated with HCC metas-
tasis (Olive et al., 2001; Yang et al., 2013). 
The High Expression in HCC lncRNA 
(termed lncRNA-HEIH) is an oncogenic 
lncRNA with a high expression in hepatocel-
lular carcinoma. This lncRNA facilitates tu-
mor growth through enhancing Zeste Homo-
log 2 in humans and may act as a critical reg-
ulatory factor in HCC progression (Yang et 
al., 2011). P73 antisense RNA 1 T (TP73-
AS1) is located at 1p36 on the human chro-
mosome and is associated with cell prolifera-
tion and tumor progression (Zang et al., 
2016). Previous studies have shown that 
TP73-AS1 might be upregulated in HCC. 
TP73-AS1 modulates HCC cell proliferation 
by miR-200a-dependent HMGB1/RAGE reg-
ulation. TP73-AS1 might compete with 
HMGB1 for miR-200a binding to inhibit 
miR-200a expression. High lncRNA-TP73-
AS1 expression in HCC is associated with a 
poorer prognosis. This lncRNA might play a 
key role in regulating the proliferation of 
HCC cells and may be a potential therapeutic 
target for HCC treatment (Li et al., 2017b). 
 
CONCLUSIONS 
Hepatocellular carcinoma is one the most 
prevalent and aggressive human malignan-
cies. Despite the use of diverse treatment 
methods, clinical prognosis remains poor. A 
number of recent studies have focused on the 
functions of lncRNAs in the initiation and 
progression of HCC. Nonetheless, our present 
understanding of lncRNAs is limited. Further 
investigations are essential to clarify the bio-
logical functions and molecular characteris-
tics of lncRNAs in HCC. 
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